Cargando…

Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort

BACKGROUND: Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallimann, M., Bouayed, K., Cannizzaro, E., Kaiser, D., Belot, A., Merlin, E., Poignant, S., Wouters, C., Hofer, F., Saurenmann, T., Koryllou, A., Carlomagno, R., Mejbri, M., Hofer, M., Theodoropoulou, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485973/
https://www.ncbi.nlm.nih.gov/pubmed/37679749
http://dx.doi.org/10.1186/s12969-023-00886-9
_version_ 1785102900947582976
author Wallimann, M.
Bouayed, K.
Cannizzaro, E.
Kaiser, D.
Belot, A.
Merlin, E.
Poignant, S.
Wouters, C.
Hofer, F.
Saurenmann, T.
Koryllou, A.
Carlomagno, R.
Mejbri, M.
Hofer, M.
Theodoropoulou, K.
author_facet Wallimann, M.
Bouayed, K.
Cannizzaro, E.
Kaiser, D.
Belot, A.
Merlin, E.
Poignant, S.
Wouters, C.
Hofer, F.
Saurenmann, T.
Koryllou, A.
Carlomagno, R.
Mejbri, M.
Hofer, M.
Theodoropoulou, K.
author_sort Wallimann, M.
collection PubMed
description BACKGROUND: Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort). METHODS: Observational patient cohort study with 201 recruited children from 4 countries (3 European, 1 North Africa) from 2005 until 2019, using retrospectively (2005–2015) and prospectively (2015–2019) routine care collected data. RESULTS: Sixty-five patients with complete follow-up data for 24 months after first diagnosis were classified as monophasic (n = 23), polyphasic (n = 6) or persistent group (n = 36) corresponding to their evolution (unique flare, recurrent flares, or persistent disease activity respectively). The patients of the persistent group were more likely to have an earlier disease onset, before the age of 6 (OR 2.57, 95%-CI 0.70–9.46), persistence of arthritis at 12-months post-diagnosis (OR 4.45, 95%-CI 0.58–34.20) and higher use of synthetic DMARD (sDMARD, OR 5.28, 95%-CI 1.39–20.01). Other variables like global assessment by physician and by patient and C Reactive Protein levels at 12-months post-diagnosis were assessed but without any predictive value after adjusting for confounding factors. CONCLUSIONS: Our results suggest that the earlier disease onset, the persistence of arthritis throughout the first year of disease evolution and the need of sDMARD might predict a persistent disease course. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12969-023-00886-9.
format Online
Article
Text
id pubmed-10485973
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104859732023-09-09 Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort Wallimann, M. Bouayed, K. Cannizzaro, E. Kaiser, D. Belot, A. Merlin, E. Poignant, S. Wouters, C. Hofer, F. Saurenmann, T. Koryllou, A. Carlomagno, R. Mejbri, M. Hofer, M. Theodoropoulou, K. Pediatr Rheumatol Online J Research Article BACKGROUND: Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort). METHODS: Observational patient cohort study with 201 recruited children from 4 countries (3 European, 1 North Africa) from 2005 until 2019, using retrospectively (2005–2015) and prospectively (2015–2019) routine care collected data. RESULTS: Sixty-five patients with complete follow-up data for 24 months after first diagnosis were classified as monophasic (n = 23), polyphasic (n = 6) or persistent group (n = 36) corresponding to their evolution (unique flare, recurrent flares, or persistent disease activity respectively). The patients of the persistent group were more likely to have an earlier disease onset, before the age of 6 (OR 2.57, 95%-CI 0.70–9.46), persistence of arthritis at 12-months post-diagnosis (OR 4.45, 95%-CI 0.58–34.20) and higher use of synthetic DMARD (sDMARD, OR 5.28, 95%-CI 1.39–20.01). Other variables like global assessment by physician and by patient and C Reactive Protein levels at 12-months post-diagnosis were assessed but without any predictive value after adjusting for confounding factors. CONCLUSIONS: Our results suggest that the earlier disease onset, the persistence of arthritis throughout the first year of disease evolution and the need of sDMARD might predict a persistent disease course. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12969-023-00886-9. BioMed Central 2023-09-07 /pmc/articles/PMC10485973/ /pubmed/37679749 http://dx.doi.org/10.1186/s12969-023-00886-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wallimann, M.
Bouayed, K.
Cannizzaro, E.
Kaiser, D.
Belot, A.
Merlin, E.
Poignant, S.
Wouters, C.
Hofer, F.
Saurenmann, T.
Koryllou, A.
Carlomagno, R.
Mejbri, M.
Hofer, M.
Theodoropoulou, K.
Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort
title Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort
title_full Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort
title_fullStr Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort
title_full_unstemmed Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort
title_short Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort
title_sort disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through jircohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485973/
https://www.ncbi.nlm.nih.gov/pubmed/37679749
http://dx.doi.org/10.1186/s12969-023-00886-9
work_keys_str_mv AT wallimannm diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT bouayedk diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT cannizzaroe diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT kaiserd diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT belota diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT merline diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT poignants diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT woutersc diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT hoferf diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT saurenmannt diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT korylloua diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT carlomagnor diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT mejbrim diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT hoferm diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort
AT theodoropoulouk diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort